Effect of β-blockers on cardiac and pulmonary events and death in older adults with cardiovascular disease and chronic obstructive pulmonary disease

Medical Care

Volumn 52, Issue 3 SUPPL. 2, 2014, Pages

  Lee, David S H ^a   Markwardt, Sheila ^a   McAvay, Gail J ^b   Gross, Cary P ^b   Goeres, Leah M ^a   Han, Ling ^b   Peduzzi, Peter ^c   Lin, Haiqun ^c   Dodson, John A ^b   Tinetti, Mary E ^b,c  

^a OREGON STATE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY   (United States)

Author keywords

B blocker; Cardiac events; Cardiovascular disease; Chronic obstructive pulmonary disease; COPD; Coronary artery disease; CVD; Multimorbidity; Multiple chronic conditions; Pulmonary events

Indexed keywords

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMORBIDITY; CONFIDENCE INTERVALS; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; ODDS RATIO; PRIMARY HEALTH CARE; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME; UNITED STATES;

EID: 84894428063     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0000000000000035     Document Type: Article

References (36)

1. Tinetti ME, Bogardus ST Jr, Agostini JV. Potential pitfalls of diseasespecific guidelines for patients with multiple diseases. N Engl J Med. 2004;351:2870-2874.
2. Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294:716-724. (Pubitemid 41159291)
3. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011. update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458-2473.
4. Steg PG, López-Sendón J, Lopez de Sa E, et al. GRACE Investigators. External validity of clinical trials in acute myocardial infarction. Arch Intern Med. 2007;167:68-73. (Pubitemid 46072409)
5. Dhruva SS, Redberg RF. Variations between clinical trial participants and Medicare beneficiaries in evidence used for Medicare National Coverage Decisions. Arch Intern Med. 2008;168:136-140. (Pubitemid 351185879)
6. Bangalore S, Gabriel Steg PG, Deedwania P, et al. Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308:1340-1349.
7. Nakatani D, Yasukhiko S, Suna S, et al. Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era. Am J Cordiol. 2013;1111:457-464.
8. van der Woude HJ, Zaagsma J, Postma DS, et al. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest. 2005;127:818-824. (Pubitemid 40775510)
9. Chang CL, Mills GD, McLachlan JD, et al. Cardio-selective and nonselective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Intern Med J. 2010;40:193-200.
10. Chen J, Radford MJ, Wang Y, et al. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol. 2001; 37:1950-1956. (Pubitemid 32499985)
11. Brooks TW, Creekmore FM, Young DC, et al. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers. Pharmacotherapy. 2007;27:684-690. (Pubitemid 46700960)
12. Rutten FH, Zuithoff NPA, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170:880-887.
13. van Gestel YR, Hoeks SE, Sin DD, et al. Impact of cardioselective betablockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med. 2008;78:695-700.
14. Short PM, Lipworth SIW, Elder DIH, et al. Effect of b blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. Br Med J. 2011;342:d2549 doi:10.1136/bmj.d2549.
15. Mitchell AA, Kaufman DW, Rosenberg L. Patterns of medication use in the United States. A Report from the Slone Survey (Internet), 2006. Available at: http://www.bu.edu/slone/SloneSurvey/SloneSurvey.htm. Accessed January 23, 2012.
16. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348:1556-1564. (Pubitemid 36437933)
17. Psaty BM, Siscovick DS. Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction. JAMA. 2010;304:897-898.
18. Vandenbrouke JP. When are observational studies as credible as randomized trials? Lancet. 2004;363:1728-1731.
19. Laupacis A, Mamdani M. Observational studies of treatment effectiveness: some cautions. Ann Intern Med. 2004;140:923-924. (Pubitemid 38685274)
20. Giordano SH, Kuo YF, Duan Z, et al. Limits of observational data in determining outcomes from cancer therapy. Am Cancer Soc. 2008;112:2456-2466.
21. Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98:253-259.
22. Larson EB. Evidence, guidelines, performance incentives, complexity, and old people: a clinician's dilemma. J Am Geriatr Soc. 2009;57: 353-354.
23. Methods guide for effectiveness and comparative effectiveness reviews. Available at: http://www.effectivehealthcare.ahrq.gov. Accessed November 11, 2011.
24. Medicare Current Beneficiary Survey. Available at: http://www.cms.hhs. gov/apps/mcbs/overview.asp. Accessed November 11, 2011.
25. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD 10 administrative data. Med Care. 2005;43:1130-1139. (Pubitemid 41587600)
26. Leon AC, Hedeker D, Teres JJ. A mixed-effect propensity adjustment for effectiveness analyses of ordered categorical doses. Stat Med. 2007;26:110-123. (Pubitemid 46099420)
27. Rosenbaum P, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
28. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281. (Pubitemid 28466823)
29. Austin PC. A critical appraisal of propensity score matching in the medical literature from 1996 to 2003. Stat Med. 2008;27:2037-2049. (Pubitemid 351772300)
30. Austin PC. The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Making. 2009;29:661-677.
31. Allison PD. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute Inc.; 1995.
32. Hosmer DWJ, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York: John Wiley & Sons Inc.; 1999.
33. Chaudhry SI, Wang Y, Gill TM, et al. Geriatric conditions and subsequent mortality in older patients with heart failure. J Am Coll Cardiol. 2010;55:309-316.
34. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
35. Freemantle N, Cleland J, Young P, et al. b-Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999; 318:1730-1737. (Pubitemid 29290470)
36. Düngen HD, Apostolovic S, Inkrot S, et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBISELD trial. Eur J Heart Fail. 2011;13:670-680.